Return to Video Library

Cathleen McCabe, MD

Share

Other videos

Inder Paul Singh, MD – Video 1

The Eye Centers of Racine & Kenosha

Inder Paul Singh, MD – Video 2

The Eye Centers of Racine & Kenosha

Michael Rom, MD

Insight Eye Center

Lisa Feulner, MD

Advanced Eye Care

Brandon Rodriguez, MD

St Luke’s Cataract and Laser Institute

Jason Bacharach, MD

North Bay Eye Associates

Mitchell Jackson, MD – Video 1

Jacksoneye

Mitchell Jackson, MD – Video 2

Jacksoneye

Robert Weinstock, MD

The Eye Institute of West Florida

Robert Osher, MD

Cincinnati Eye Institute

John Hovanesian, MD

Harvard Eye Associates

Nathan Radcliffe, MD

New York Eye Surgery Center

Other videos

Nathan Radcliffe, MD

New York Eye Surgery Center

John Hovanesian, MD

Harvard Eye Associates

Robert Osher, MD

Cincinnati Eye Institute

Robert Weinstock, MD

The Eye Institute of West Florida

Mitchell Jackson, MD – Video 2

Jacksoneye

Mitchell Jackson, MD – Video 1

Jacksoneye

Jason Bacharach, MD

North Bay Eye Associates

Brandon Rodriguez, MD

St Luke’s Cataract and Laser Institute

Lisa Feulner, MD

Advanced Eye Care

Michael Rom, MD

Insight Eye Center

Inder Paul Singh, MD – Video 2

The Eye Centers of Racine & Kenosha

Inder Paul Singh, MD – Video 1

The Eye Centers of Racine & Kenosha

INDICATION AND USAGE

DEXYCU^® (dexamethasone intraocular suspension) 9% is indicated for the treatment of postoperative inflammation.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

None.

WARNINGS AND PRECAUTIONS

Increase in Intraocular Pressure

Prolonged use of corticosteroids, including DEXYCU, may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision
Steroids should be used with caution in the presence of glaucoma

Delayed Healing

The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation
In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of corticosteroids

Exacerbation of Infection

The use of DEXYCU, as with other ophthalmic corticosteroids, is not recommended in the presence of most active viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal disease of ocular structures
Use of a corticosteroid in the treatment of patients with a history of herpes simplex requires caution and may prolong the course and may exacerbate the severity of many viral infections
Fungal infections of the cornea are particularly prone to coincidentally develop with long-term local steroid application and must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal culture should be taken when appropriate
Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infection

Cataract Progression

The use of corticosteroids in phakic individuals may promote the development of posterior subcapsular cataracts

ADVERSE REACTIONS

The most commonly reported adverse reactions occurred in 5-15% of subjects and included increases in intraocular pressure, corneal edema and iritis

Please click here for full Prescribing Information.

References

1. DEXYCU^® (dexamethasone intraocular suspension) 9% full U.S. Prescribing Information. EyePoint Pharmaceuticals, Inc. June 2020. 2. Data on file. EyePoint Pharmaceuticals, Inc. 3. Donnenfeld E, Holland E. Dexamethasone intracameral drug-delivery suspension for inflammation associated with cataract surgery: a randomized, placebo-controlled, phase III trial. Ophthalmology. 2018;125(6):799-806.

INDICATION AND USAGE

DEXYCU^® (dexamethasone intraocular suspension) 9% is indicated for the treatment of postoperative inflammation.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

None.

DEXYCU, the DEXYCU logo, and the EyePoint logo are registered trademarks of EyePoint Pharmaceuticals, Inc. ©2022 EyePoint Pharmaceuticals, Inc. All rights reserved. ImprimisRx is a registered trademark of Harrow Health, Inc. ©2022 ImprimisRx. All rights reserved. 1000 Aviara Parkway, Suite 220 Carlsbad, CA 92011

Text Us: (858) 264-2082 | Fax: (858) 345-1745

Site Map | Terms and Conditions | Privacy Policy

THIS SITE IS INTENDED FOR U.S. HEALTHCARE PROFESSIONALS ONLY.

03/2022

US-DEX-2000003

04/2021

US-DEX-2100044

04/2021

US-DEX-2100055

10/2019

US-DEX-1900213

09/2020

US-DEX-2000144

11/2020

US-DEX-2000175

09/2021

US-DEX-2100183

12/2020

US-DEX-2000179

06/2021

US-DEX-2100128

09/2021

US-DEX-2100226

09/2021

US-DEX-2100161

09/2021

US-DEX-2100187

09/2021

US-DEX-2100227